Acetylcholine Release Inhibitors
"Acetylcholine Release Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that block release of the neurotransmitter ACETYLCHOLINE.
| Descriptor ID |
D065087
|
| MeSH Number(s) |
D27.505.519.562.061 D27.505.519.625.120.069 D27.505.696.577.120.069
|
| Concept/Terms |
Acetylcholine Release Inhibitors- Acetylcholine Release Inhibitors
- Inhibitors, Acetylcholine Release
- Acetylcholine Release Antagonists
- Antagonists, Acetylcholine Release
- Acetylcholine Release Blockers
- Blockers, Acetylcholine Release
- Release Blockers, Acetylcholine
|
Below are MeSH descriptors whose meaning is more general than "Acetylcholine Release Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Acetylcholine Release Inhibitors".
This graph shows the total number of publications written about "Acetylcholine Release Inhibitors" by people in this website by year, and whether "Acetylcholine Release Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Acetylcholine Release Inhibitors" by people in Profiles.
-
Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak Turk J Med Sci. 2021 04 30; 51(2):385-392.
-
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019 Mar 07; 20(1):26.
-
Pain and Muscles Properties Modifications After Botulinum Toxin Type A (BTX-A) and Radial Extracorporeal Shock Wave (rESWT) Combined Treatment. Endocr Metab Immune Disord Drug Targets. 2019; 19(8):1127-1133.
-
Botulinum toxin A (BT-A) versus low-level laser therapy (LLLT) in chronic migraine treatment: a comparison. Arq Neuropsiquiatr. 2018 10; 76(10):663-667.
-
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018 Sep 26; 19(1):91.
-
Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Rev Neurother. 2018 02; 18(2):167-176.
-
Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain. 2017 Sep 06; 18(1):93.
-
Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec; 37(14):1384-1397.
-
Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. J Headache Pain. 2017 Dec; 18(1):66.